Logo

The active immunological profile in patients with primary Sjögren's syndrome is restricted to typically encountered autoantibodies

1, 2, 3, 4, 5, 6

  1. Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France.
  2. Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest; and Unit of Rheumatology, CHRU Cavale Blanche, Brest, France.
  3. Unit of Rheumatology, CHRU Cavale Blanche, Brest; and INSERM ESPRI, ERI29/EA2216, Innovative Medicines Initiative PRECISESADS, European University of Brittany, Brest, France.
  4. Unit of Rheumatology, CHRU Cavale Blanche, Brest; and INSERM ESPRI, ERI29/EA2216, Innovative Medicines Initiative PRECISESADS, European University of Brittany, Brest, France.
  5. Unit of Rheumatology, CHRU Cavale Blanche, Brest; and INSERM ESPRI, ERI29/EA2216, Innovative Medicines Initiative PRECISESADS, European University of Brittany, Brest, France.
  6. Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest; and INSERM ESPRI, ERI29/EA2216, Innovative Medicines Initiative PRECISESADS, European University of Brittany, Brest, France. yves.renaudineau@univ-brest.fr

CER9167 Submission on line
2016 Vol.34, N°4 - PI 0722
Letters to the Editor

Free to view (click on article PDF icon to read the article)

Rheumatology Article

 

PMID: 27191916 [PubMed]

Received: 04/12/2015 - Accepted : 01/02/2016 - In Press: 09/05/2016 - Published: 14/07/2016